Powered by

Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial

Aug 06, 2019 - GlobeNewswire

-EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo--Patients Dosed with EDP1815 Showed a Reduction in Mean Lesion Severity Score vs. Placebo--Reductions Observed in Cellular Histological and Blood Immune Cell Biomarkers Consistent with Clinical Response --Phase 2 Initiation Planned for Early 2020--First in Human Data Suggest that Oral Biologics that Act on Cells in the Small Intestine Modulate Systemic Inflammation--Management to Host Conference Call at 8:30 a.m. ET-

CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced positive interim clinical data from the first cohort of patients with mild to moderate psoriasis from its ongoing Phase 1b trial of EDP1815, its clinical candidate for the treatment of inflammatory diseases. EDP1815 was well tolerated with no overall difference reported from pl...